Claudia VOENA

Dr. Claudia VOENA

orcid

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 December 2018 in Nature Medicine
Verified
Journal Article
Closed access
MMMatteo Menotti
Matteo Menotti
Chiara AmbrogioChiara Ambrogio
Chiara Ambrogio
TCTaek-Chin Cheong
Taek-Chin Cheong
CPChiara Pighi
Chiara Pighi
IMInes Mota
Ines Mota
Roberto ChiarleRoberto Chiarle
Roberto Chiarle

3 February 2022 in Blood
Verified
Journal Article
Open access
PDF file
EAElif Karaca Atabay
Elif Karaca Atabay
CMCarmen Mecca
Carmen Mecca
QWQi Wang
Qi Wang
Chiara AmbrogioChiara Ambrogio
Chiara Ambrogio
IMInes Mota
Ines Mota
Roberto ChiarleRoberto Chiarle
Roberto Chiarle
Anaplastic large cell lymphomas (ALCLs) frequently carry oncogenic fusions involving the anaplastic lymphoma kinase (ALK) gene. Targeting ALK using tyrosine kinase inhibitors (TKIs) is a therapeutic option in cases relapsed after chemotherapy, but TKI resistance may develop. By applying genomic loss-of-function screens, we identified PTPN1 and PTPN2 phosphatases as consistent top hits driving resistance to ALK TKIs in ALK+ ALCL. Loss of either PTPN1 or PTPN2 induced resistance to ALK TKIs in vitro and in vivo. Mechanistically, we demonstrated that PTPN1 and PTPN2 are phosphatases that bind to and regulate ALK phosphorylation and activity. In turn, oncogenic ALK and STAT3 repress PTPN1 transcription. We found that PTPN1 is also a phosphatase for SHP2, a key mediator of oncogenic ALK signaling. Downstream signaling analysis showed that deletion of PTPN1 or PTPN2 induces resistance to crizotinib by hyperactivating SHP2, the MAPK, and JAK/STAT pathways. RNA sequencing of patient samples that developed resistance to ALK TKIs showed downregulation of PTPN1 and PTPN2 associated with upregulation of SHP2 expression. Combination of crizotinib with a SHP2 inhibitor synergistically inhibited the growth of wild-type or PTPN1/PTPN2 knock-out ALCL, where it reverted TKI resistance. Thus, we identified PTPN1 and PTPN2 as ALK phosphatases that control sensitivity to ALK TKIs in ALCL and demonstrated that a combined blockade of SHP2 potentiates the efficacy of ALK inhibition in TKI-sensitive and -resistant ALK+ ALCL.

30 October 2014 in Cancer Research
Verified
Journal Article
Closed access
PDF file
CMCinzia Martinengo
Cinzia Martinengo
TPTeresa Poggio
Teresa Poggio
MMMatteo Menotti
Matteo Menotti
MSMaria Stella Scalzo
Maria Stella Scalzo
CMCristina Mastini
Cristina Mastini
Roberto ChiarleRoberto Chiarle
Roberto Chiarle
Rearrangements involving the anaplastic lymphoma kinase (ALK) gene are defining events in several tumors, including anaplastic large-cell lymphoma (ALCL) and non–small cell lung carcinoma (NSCLC). In such cancers, the oncogenic activity of ALK stimulates signaling pathways that induce cell transformation and promote tumor growth. In search for common pathways activated by oncogenic ALK across different tumors types, we found that hypoxia pathways were significantly enriched in ALK-rearranged ALCL and NSCLC, as compared with other types of T-cell lymphoma or EGFR- and K-RAS–mutated NSCLC, respectively. Consistently, in both ALCL and NSCLC, we found that under hypoxic conditions, ALK directly regulated the abundance of hypoxia-inducible factors (HIF), which are key players of the hypoxia response in normal tissues and cancers. In ALCL, the upregulation of HIF1α and HIF2α in hypoxic conditions required ALK activity and its downstream signaling proteins STAT3 and C/EBPβ. In vivo, ALK regulated VEGFA production and tumor angiogenesis in ALCL and NSCLC, and the treatment with the anti-VEGFA antibody bevacizumab strongly impaired ALCL growth in mouse xenografts. Finally, HIF2α, but not HIF1α, was required for ALCL growth in vivo whereas the growth and metastasis potential of ALK-rearranged NSCLC required both HIF1α and HIF2α. In conclusion, we uncovered an ALK-specific regulation of the hypoxia response across different ALK+ tumor types and propose HIFs as a powerful specific therapeutic target in ALK-rearranged ALCL and NSCLC. Cancer Res; 74(21); 6094–106. ©2014 AACR.

10 July 2023 in Nature Cancer
Verified
Journal Article
Closed access
PDF file
IMInes Mota
Ines Mota
EPEnrico Patrucco
Enrico Patrucco
CMCristina Mastini
Cristina Mastini
NMNavin R. Mahadevan
Navin R. Mahadevan
TTTran C. Thai
Tran C. Thai
Roberto ChiarleRoberto Chiarle
Roberto Chiarle

7 March 2025 in Nature Reviews Cancer
Verified
Journal Article
Closed access
PDF file
CVClaudia VOENA
Claudia VOENA
Chiara AmbrogioChiara Ambrogio
Chiara Ambrogio
FIFabio Iannelli
Fabio Iannelli
Roberto ChiarleRoberto Chiarle
Roberto Chiarle

1 February 2016
Verified
Journal Article
Closed access
CVClaudia VOENA
Claudia VOENA
Roberto ChiarleRoberto Chiarle
Roberto Chiarle